Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KB301 for skin aging
NCT04540900Phase 1Active, not recruiting
- Sponsor
- Krystal Biotech, Inc.
- Start
- Oct 2020
- Primary completion
- Oct 2024
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rhytides comparing KB301 with Placebo (2 arms). Primary endpoint: Assessment of the safety profile of KB301 at 4 months. Started Oct 2020; status: active, not recruiting.
02
Drugs
KB301
03
Conditions
rhytides
Beyond the preview
Go deeper on NCT04540900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540900.